FOXA1 is a pioneer factor that can reposition AR and other transcription factors to new super‐enhancers, altering gene expression patterns and promoting prostate cancer progression.[22] Impeding SWI/SNF‐mediated enhancer accessibility represents a promising therapeutic approach for enhancer‐addicted CRPC.[23]. Here, AR is linked to prostate cancer.